Pioneers of Piezo Shockwave Technology

How Richard Wolf & Elvation Medical Shaped ESWT

On June 1, 1983, Richard Wolf filed a patent for a “piezoelectric transducer for the destruction of concretions inside the body.” It was the beginning of a technology that would become the foundation of today’s piezoelectric shockwave.

Today, modern shockwave therapy is indispensable in orthopedics, pain therapy and urology. Patients around the world benefit from this noninvasive technology, yet its history began with a simple but groundbreaking idea: using sound waves for healing. For Richard Wolf and Elvation Medical, this idea grew into a continuous path of innovation that has shaped the development of piezoelectric shockwave technology for more than four decades.

The Birth of Piezo Shockwave Technology

In the 1970s, shockwave research was still in its infancy. Inspired by observations from aerospace research, scientists began investigating the effects of pressure waves on biological tissue.

While early companies experimented with spark-gap systems, Richard Wolf GmbH pursued a different path that promised quieter, more precise and more patient-friendly treatment.

The crucial physical principle was the inverse piezoelectric effect. When electrical voltage is applied to piezo ceramics, they change their shape by tiny amounts and generate a pressure wave. This principle allowed for precise energy focusing and targeted treatment inside the body.

In 1984, the first prototype emerged: the PiezoLith 2200, featuring an integrated ultrasound probe for kidney stone localization. Shortly after, the PiezoLith 2300 followed—the world’s first series-produced device capable of treating kidney stones without anesthesia.

This milestone marked the start of a new era. Shockwave therapy became a precise, safe and comfortable procedure in urology.

From Kidney Stones to Regeneration

What began as a method of stone fragmentation soon became the basis for one of the most dynamic developments in modern medicine: Extracorporeal Shockwave Therapy (ESWT).

In the 1990s, researchers discovered by chance that shockwaves can stimulate bone growth. This sparked the idea of using shockwaves not only for mechanical stone disintegration but also to promote tissue healing. Scientists found that shockwaves trigger biological responses: improving microcirculation, promoting the release of growth factors and supporting tissue regeneration. Today, this mechanism is known as mechanotransduction.

Early orthopedic and rehabilitative applications quickly produced impressive results. These clinical successes led to the development of dedicated piezoelectric systems for ESWT.

In 1998, Richard Wolf introduced the Piezoson 300, the first compact ESWT device with integrated ultrasound localization. Three years later came the Piezoson 100, then the smallest ESWT system in the world, which further advanced the principle of noninvasive therapy. It enabled truly flexible use in practices, clinics and sports medicine.

In the years that followed, the technology became even more precise. With the patented Double-Layer Technology (DLT), output and penetration depth could be significantly increased without compromising tissue protection. With each new therapy source, whether finely focused or high-performance, the system’s variability grew. Users could now tailor energy settings precisely to the indication and tissue depth.

The PiezoWave² continued this development: modular in design, intuitive to operate, and compatible with all therapy sources.

In 2009, the world’s first line-focused and patented therapy source (FBL10x5G2) entered the market. Beyond orthopedic treatments, it opened new possibilities in dermatology and especially in urology for the treatment of erectile dysfunction.

In 2021, the PiezoWave^2T, followed, the most technologically advanced system to date. With a touch interface, frequencies up to 12 Hz and the so-called T-Mode (T-Ramp and T-Burst), it enables expanded therapeutic applications, from dynamic treatment workflows to flexibly adjustable therapy parameters.

Today, the PiezoWave^2T brings together the best of four decades of development: precise focusing, high energy efficiency, durability and an interface that unites research and clinical practice on a single platform.

Pioneers of Piezoelectric Shockwave Technology

From the first piezoelectric transducers of the 1980s to today’s PiezoWave^2T generation, shockwave therapy has evolved from a revolutionary idea into an established clinical modality. This path has been defined by scientific curiosity, technological excellence and a clear vision: continually expanding the boundaries of noninvasive therapy.

This vision has shaped the partnership between Richard Wolf and ELvation Medical since 2009. While Richard Wolf continually refines piezoelectric technology as developer and manufacturer, Elvation Medical ensures through cooperation with leading clinical partners that it unfolds its full potential in everyday medical use.

Anyone considering the purchase of an ESWT shockwave therapy device today will find in the PiezoWave^2T one of the most advanced forms of piezoelectric shockwave therapy and can rely on devices characterized by quality, precision and experience.

Looking Ahead: Research, Evidence and New Perspectives

Piezoelectric shockwave therapy has long established itself beyond orthopedics. Research findings and clinical studies continue to open new indications in urology, pain medicine, dermatology and veterinary medicine.

In cooperation with renowned research partners, such as RWTH Aachen University, Elvation Medical and Richard Wolf continue to investigate the biological mechanisms of shockwaves. The goal is to better understand regenerative processes and to optimize therapy protocols based on evidence.

The core idea remains unchanged: patient-centered innovation through precise technology. Forward-looking projects, digital applications and international training initiatives will continue to shape this path, always with a focus on safety, quality and medical advancement.